A randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG 1406) showed that the addition of vemurafenib to the combination of cetuximab and irinotecan could result in a prolongation of progression-free survival (PFS) and a higher disease control rate, suggesting that simultaneous EGFR and BRAF inhibition is effective in BRAF V600-mutated CRC. Here, BRAF is linked to colorectal carcinoma.